SCHEMBL334965

SCHEMBL334965

CC(NCCN)c1ccc(N2CC2c2ccncc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.51
GAA P10253 1/20 0.51
NPSR1 Q6W5P4 3/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
KMT2A Q03164 3/20 0.34
BRAF P15056 1/20 0.33
CYP3A4 P08684 2/20 0.33
CHRM2 P08172 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CHRM1 P11229 1/20 0.33
SMPD1 P17405 1/20 0.33
DRD1 P21728 1/20 0.33
TBXA2R P21731 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243828 0.82 GAA (0.48) L3MBTL1GAALMNAACACB
SCHEMBL10730601 0.77 GAA (0.46) L3MBTL1GAANPSR1MAPTLMNA
SCHEMBL18575578 0.72 HTR1A (0.50) NPSR1MAPTLMNAKMT2ACYP3A4
SCHEMBL10735443 0.68 ALDH1A1 (0.45) L3MBTL1GAANPSR1MAPTLMNA
SCHEMBL335053 0.67 ALDH1A1 (0.47) GAAMAPTLMNAKMT2ACYP3A4
SCHEMBL335243 0.67 RORC (0.42) LMNACYP3A4CHRM2HTR1AADRA2A
SCHEMBL18575438 0.66 SMN1; SMN2 (0.47) NPSR1MAPTLMNATDP1KMT2A
SCHEMBL335100 0.65 L3MBTL1 (0.61) L3MBTL1GAANPSR1MAPTLMNA
SCHEMBL335368 0.65 NOTUM (0.59) GAAMAPTLMNATDP1KMT2A
SCHEMBL18575437 0.65 PKM (0.57) GAAMAPTLMNAKMT2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 L3MBTL1 2853/4885GAA 551/4885NPSR1 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.